source
- Pediatric rare cancer research draws steady investment despite biotech market volatilityThe article notes that pediatric rare cancers continue to attract investment because they address the greatest unmet medical needs and allow clear measurement of patient impact. Even as the biotec…
- Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialPlus news about AC Immune, Lilly's Adverum and SiranBio. 🤝 Eli Lilly signs vaccine deal with Amplitude: The companies will work to develop vaccines using “trans-amplifying RNA,” or taRNA, for infe…Endpoints · 1h ago↗ source
- Tolerance Bio secures up to $260 M for thymus‑targeting fusion protein, moves into Phase 2 trials